Literature DB >> 20953960

Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.

Gulsen Akman-Demir1, Erdem Tüzün, Patrick Waters, Sema Içöz, Murat Kürtüncü, Sven Jarius, Zuhal Yapıcı, Melike Mutlu, Nilüfer Yeşilot, Angela Vincent, Mefkure Eraksoy.   

Abstract

Neuromyelitis optica (NMO) is an inflammatory/demyelinating disorder predominantly affecting the optic nerves and spinal cord. Recent findings showed an underlying humoral abnormality in NMO, characterized by a serum antibody against aquaporin-4 (Aqp-4-Ab). In this study, we evaluated the Aqp-4-Ab status among Turkish patients with NMO to determine the clinical and prognostic relevance. Serum samples from 35 consecutive patients with NMO followed at a single center and diagnosed according to the 2006 revised criteria, were evaluated for Aqp-4-Ab. All samples were obtained during a relapse prior to any immunosuppressive treatment. Aqp-4-Ab was positive in 21/35 (60%) patients. Among these cases, 11 had an EDSS of 6.0 or more, whereas only two patients in the seronegative group had such severe disability (p < 0.05). Overall, seropositive cases had a mean EDSS score of 5.1 ± 2.2 compared with 3.5 ± 1.7 in seronegative cases (p < 0.01). There were trends towards female predominance in seropositive cases and a monophasic course predominance in seronegative cases. Disease duration, age at onset, number of attacks and time to definite NMO did not differ between groups. Our findings in this single-center cohort suggest that the presence of Aqp-4-Ab might have a prognostic significance indicating a more severe disease course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20953960     DOI: 10.1007/s00415-010-5780-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.

Authors:  I Nakashima; K Fujihara; I Miyazawa; T Misu; K Narikawa; M Nakamura; S Watanabe; T Takahashi; S Nishiyama; Y Shiga; S Sato; B G Weinshenker; Y Itoyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02-27       Impact factor: 10.154

2.  NMO-IgG in the diagnosis of neuromyelitis optica.

Authors:  S Jarius; D Franciotta; R Bergamaschi; H Wright; E Littleton; J Palace; R Hohlfeld; A Vincent
Journal:  Neurology       Date:  2007-02-07       Impact factor: 9.910

3.  Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.

Authors:  J de Seze; T Stojkovic; D Ferriby; J-Y Gauvrit; C Montagne; F Mounier-Vehier; A Verier; J-P Pruvo; J-C Hache; P Vermersch
Journal:  J Neurol Sci       Date:  2002-05-15       Impact factor: 3.181

4.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

7.  Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.

Authors:  Patrick Waters; Sven Jarius; Edward Littleton; Maria Isabel Leite; Saiju Jacob; Bryony Gray; Ruth Geraldes; Thomas Vale; Anu Jacob; Jacqueline Palace; Susan Maxwell; David Beeson; Angela Vincent
Journal:  Arch Neurol       Date:  2008-07

8.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

9.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Authors:  Samira Saadoun; Patrick Waters; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Brain       Date:  2010-01-04       Impact factor: 13.501

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  19 in total

1.  Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.

Authors:  Yujuan Jiao; James P Fryer; Vanda A Lennon; Sarah M Jenkins; Amy M L Quek; Carin Y Smith; Andrew McKeon; Chiara Costanzi; Raffaele Iorio; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock
Journal:  Neurology       Date:  2013-08-30       Impact factor: 9.910

Review 2.  Multiple Sclerosis: Diagnosis and Differential Diagnosis.

Authors:  Sami Ömerhoca; Sinem Yazici Akkaş; Nilüfer Kale İçen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

3.  Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.

Authors:  Hongyang Li; Yanling Wang; Quangang Xu; Aidi Zhang; Huanfen Zhou; Shuo Zhao; Hao Kang; Chunxia Peng; Shanshan Cao; Shihui Wei
Journal:  J Neurol       Date:  2015-07-11       Impact factor: 4.849

4.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

Review 5.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

6.  Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.

Authors:  Maureen A Mealy; Su-Hyun Kim; Felix Schmidt; Reydmar López; Jorge A Jimenez Arango; Friedemann Paul; Dean M Wingerchuk; Benjamin M Greenberg; Ho Jin Kim; Michael Levy
Journal:  Mult Scler       Date:  2017-08-31       Impact factor: 6.312

7.  'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica.

Authors:  S Jarius; B Wildemann
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

Review 8.  [Neuromyelitis optica].

Authors:  B Wildemann; S Jarius; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 9.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

10.  Clinical Features of the Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Arman Çakar; Canan Ulusoy; Tuncay Gündüz; Cem İsmail Küçükali; Murat Kürtüncü
Journal:  Noro Psikiyatr Ars       Date:  2019-08-26       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.